AI TRIPEPTIDE 29

AI TriPeptide 29

LA EXOME’s tripeptide 29 is formed by screening 2,826 possible tripeptide combinations derived from 45 human collagen peptide sequences, followed by frequency-based algorithm analysis of 940 sequence patterns to identify optimal candidates.

Multi-Pathway Skin Rejuvenation

A Comprehensive Approach to DNA Protection, Collagen Stimulation & Brightening

Analyzed in vitro using human skin fibroblast cells, with collagen gene expression measured via fluorescence-based assay after 24-hour treatment.

Clinically validated across multiple biological pathways, this advanced ingredient delivers comprehensive skin rejuvenation by acting at both the cellular and structural levels. It helps protect DNA from UV and oxidative damage, while modulating key signaling pathways to reduce inflammation and cellular stress, creating an optimal environment for healthy skin function. At the same time, it activates longevity-related proteins and significantly enhances the expression of multiple collagen types (I, III, IV, VII), supporting improved firmness, elasticity, and skin integrity. Complementing these effects, it also reduces transepidermal water loss and inhibits melanin production, promoting long-lasting hydration and a more even, radiant complexion.

The result is visibly smoother, firmer, and brighter skin—empowered from within for a refined, youthful appearance.

Results

Clinically demonstrated in vitro, Tripeptide-29 significantly boosts Type I collagen production by up to 148%, outperforming conventional collagen boosters and supporting visibly firmer, more youthful-looking skin.

Derived from in vitro testing on human skin fibroblast cells, where Type I collagen production was quantified using ELISA after 24-hour ingredient exposure.

Elasticity Restoration

Advanced Elasticity Restoration

Clinically evaluated in vitro, this ingredient demonstrates a powerful ability to enhance skin elasticity at the molecular level by significantly increasing the expression of key elastic proteins. It boosts elastin, the essential protein responsible for skin’s ability to stretch and rebound, while also upregulating Fibulin-5, a critical component that supports the formation and integrity of elastic fibers.

By strengthening the skin’s elastic network, it helps improve resilience, reduce the appearance of sagging, and restore a firmer, more lifted look. The result: skin that feels more supple, resilient, and visibly youthful with enhanced bounce and structural support

Unlock Your Skin’s Potential

Collagen Preservation & Anti-Aging Protection

Clinically demonstrated in vitro, La Exomé Tripeptide-29 effectively reduces collagen-degrading enzymes (MMP-1 and MMP-3), helping to protect the skin’s structural integrity. By limiting collagen breakdown and preserving elasticity, it supports firmer, smoother skin and helps slow visible signs of aging such as wrinkles and sagging.

CLINICAL TRIAL

Clinically Proven Skin Firming Performance

A controlled in vivo clinical study was conducted to evaluate the efficacy of La Exomé Tripeptide 29 on skin firmness. The trial involved 32 middle-aged women (average age 46.4 ± 1.2 years) who applied a formulation containing 0.1% La Exomé Tripeptide 29 once daily over a 28-day period. Skin firmness was objectively measured using standardized F4 parameters. Results demonstrated a visible improvement as early as day 14, with continued enhancement through day 28. Compared to the baseline formulation, the test group showed a statistically significant increase in skin firmness, reaching up to +13.5%. These findings confirm that La Exomé Tripeptide 29 delivers measurable and effective firming benefits, supporting its role as a high-performance active for improving skin tightness and overall skin quality.

A controlled in vivo clinical study demonstrated that Tripeptide 29 significantly improves skin elasticity. Conducted on 32 middle-aged women over 28 days, participants applied a formulation containing 0.1% Tripeptide 29 once daily. Skin elasticity, measured by the R2 parameter (indicating how well skin bounces back), showed visible improvement as early as Day 14 and continued to increase through Day 28. Compared to the base formula, the Tripeptide 29 formulation delivered markedly superior results, achieving an overall improvement of up to +30.6%. These findings confirm that consistent use enhances skin’s resilience, firmness, and ability to recover, resulting in healthier, more elastic-looking skin.

Clinical Trial: Boost Fibronectin Production

Clinically evaluated in vitro, La Exomé Tripeptide 29 significantly enhances the synthesis of key structural proteins that support skin firmness and integrity. By boosting fibronectin production—an essential component that anchors and stabilizes collagen and elastin networks—it helps reinforce the skin’s underlying architecture. This results in improved skin strength, resilience, and overall firmness, contributing to a smoother, more lifted, and youthful-looking complexion

Clinical Trial: Boost Fibronectin Production

Clinically Proven Cellular Inflammation Reduction

La Exomé Tripeptide-29 has been clinically shown to effectively calm inflammation at the cellular level, reducing key inflammatory signals (IL-6) by approximately 34%. By targeting one of the root causes of skin irritation and aging, it helps soothe stressed skin cells, visibly reducing redness while supporting a healthier, more balanced complexion.

Clinically Proven Cellular Inflammation Reduction

Clinical Trial: Improves Skin Hydration

A controlled in vivo clinical study demonstrated that La Exomé Tripeptide 29 delivers significant improvements in skin hydration. Conducted on 32 middle-aged women over a 28-day period, participants applied a formulation containing 0.1% La Exomé Tripeptide 29 once daily. Skin hydration, measured at the stratum corneum (outer skin layer), showed noticeable increases as early as Day 14, with further enhancement by Day 28. Compared to a baseline formula, the Tripeptide 29 formulation achieved a marked improvement of up to +44.4% in moisture levels. These results confirm its strong moisturizing efficacy, supporting its role in enhancing skin smoothness, softness, and overall hydration for healthier-looking skin.

Clinical Trial: Improves Skin Hydration

Clinical Trial: Reduce Redness

A clinical study on 32 women showed that using 0.1% La Exomé Tripeptide 29 daily for 28 days helps reduce visible skin redness. Improvements were seen as early as 14 days, with continued reduction over time, resulting in calmer, less irritated-looking skin by up to 7.5%.

Clinical Trial: Reduce Redness

Skin Penetration Test

An ex vivo skin penetration study was conducted using pig skin and a Franz diffusion cell system over 6 hours to evaluate La Exomé Tripeptide 29. The results showed that 0.38–0.54% of the ingredient successfully penetrated through the skin, while 0.21–0.35% remained within the skin layers, demonstrating its ability to effectively absorb and be retained for active skin benefits.